FDA clears Xcision's breast cancer radiotherapy device
Medical technology company Xcision Medical Systems has received 510(k) clearance...Read more on AuntMinnie.com
James S. Lawson, Brian Salmons, Wendy K. Glenn
Scientists identify where hormone-fueled breast cancer cells derive their energy from, and they find a way to block their access to it.
Qi Li, Xiaoxi Kan, Jie Yin, Lidong Sun, Yajie Wang, Yujie Li, Qing Yang, Hongbin Xiao, Ying Chen, Xiaogang Weng, Weiyan Cai, Xiaoxin Zhu
Abstract Radiotherapy (RT) is the standard treatment for breast cancer patients after conserving surgery or mastectomy when patients are at high risk of relapse. Major obstacles to appropriate RT delivery are journey times. Since studies on access to RT were carried out mostly in large countries, this study investigated factors in an Italian region and the influence of RT delivery on survival. A total of 4735 female candidates for RT were included in the study. A geographic information system calculated journey times from patients' homes and surgery hospitals to RT centers. Logistic regression analyzed the influence of jou...
This study revealed that the SALL4 ‐ KHDRBS3 network augments stemness through modulation of CD44 splicing in basal‐like breast cancer. This network enhances anoikis resistance for stemness. This study may contribute to the establishment of therapies targeting cancer stemness.
AbstractPurposePrimary breast lymphoma (PBL) comprises
IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer, Published online: 22 January 2018; doi:10.1038/s41388-017-0027-9IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer
Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination, Published online: 22 January 2018; doi:10.1038/s41388-017-0069-zGrowth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination
Isn't that a warm fuzzy feeling? Now I want toask my oncologist if I have this factor. But first let me see if I can explain it. This is the precis:" Researchers at Karolinska Institutet in Sweden have discovered that the risk of death from breast cancer is twice as high for patients with high heterogeneity of the estrogen receptor within the same tumour as compared to patients with low heterogeneity. The study, which is published in The Journal of the National Cancer Institute, also shows that the higher risk of death over a span of 25 years is independent of other known tumour markers and also holds true for Luminal...